Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.65 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CPS1 | P31327 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095538 | 1.00 | ESR1 (0.65) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL1095168 | 0.91 | ESR1 (0.52) | ESR1ESR2ABHD6HSD11B1NOTUM | |
| SCHEMBL1094619 | 0.86 | ESR1 (0.62) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL1095121 | 0.85 | ESR1 (0.61) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL1095554 | 0.85 | ESR1 (0.61) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL1095164 | 0.85 | ESR1 (0.61) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL6656989 | 0.84 | ESR1 (0.60) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL1095297 | 0.84 | ESR2 (0.60) | ESR1ESR2ABHD6DRD1 | |
| SCHEMBL4932882 | 0.84 | ESR2 (0.60) | ESR1ESR2ABHD6DRD1 | |
| SCHEMBL15290710 | 0.84 | ESR1 (0.44) | ESR1ESR2ABHD6DRD1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | ESR1 1181/4885ESR2 456/4885ABHD6 1206/4885 |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | ESR1 1192/4885ESR2 448/4885ABHD6 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.